Reverse remodeling in heart failure--mechanisms and therapeutic opportunities (Q37964927)

26 August 2017

title

Reverse remodeling in heart failure--mechanisms and therapeutic opportunities (English)

1 reference

26 August 2017

0 references

Norimichi Koitabashi

1

1 reference

26 August 2017

David A Kass

series ordinal

2

1 reference

26 August 2017

language of work or name

English

0 references

publication date

6 December 2011

1 reference

Nature Reviews Cardiology

26 August 2017

published in

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

147-157

1 reference

https://scigraph.springernature.com/pub.10.1038/nrcardio.2011.172

26 August 2017

exact match

0 references

cites work

Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Controversies in ventricular remodelling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Molecular pathways underlying cardiac remodeling during pathophysiological stimulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Reversing chronic remodeling in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Influence of chronic captopril therapy on the infarcted left ventricle of the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Left ventricular radius to wall thickness ratio

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

The progression of hypertensive heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Progression from normal to reduced left ventricular ejection fraction in patients with concentric left ventricular hypertrophy after long-term follow-up

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Tackling heart failure in the twenty-first century

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Reverse remodeling from cardiomyoplasty in human heart failure. External constraint versus active assist

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endothelin-1 from fibroblasts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes. The critical role of Ca(2+)-dependent signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Angiotensin II type 2 receptor signaling attenuates aortic aneurysm in mice through ERK antagonism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Genetically modified mouse models used for studying the role of the AT2 receptor in cardiac hypertrophy and heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Cardiac nitric oxide production due to angiotensin-converting enzyme inhibition decreases beta-adrenergic myocardial contractility in patients with dilated cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Aldosterone receptor blockade prevents the transition to cardiac pump dysfunction induced by beta-adrenoreceptor activation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocard

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Adrenergic effects on the biology of the adult mammalian cardiocyte

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Beta-blockers restore calcium release channel function and improve cardiac muscle performance in human heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Mapping of regional myocardial strain and work during ventricular pacing: experimental study using magnetic resonance imaging tagging

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Pathobiology of left ventricular dyssynchrony and resynchronization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Relation between local myocardial growth and blood flow during chronic ventricular pacing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Tissue Doppler echocardiographic evidence of reverse remodeling and improved synchronicity by simultaneously delaying regional contraction after biventricular pacing therapy in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

The effect of cardiac resynchronization on morbidity and mortality in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Rethinking Resynch: Exploring Mechanisms of Cardiac Resynchroniztion Beyond Wall Motion Control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Electrophysiological consequences of dyssynchronous heart failure and its restoration by resynchronization therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Cardiac resynchronization therapy corrects dyssynchrony-induced regional gene expression changes on a genomic level.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Redox regulation of mitochondrial ATP synthase: implications for cardiac resynchronization therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Regression of cellular hypertrophy after left ventricular assist device support

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Neurohormonal changes after implantation of a left ventricular assist system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Altered myocardial Ca2+ cycling after left ventricular assist device support in the failing human heart.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Clinical recovery from end-stage heart failure using left-ventricular assist device and pharmacological therapy correlates with increased sarcoplasmic reticulum calcium content but not with regression of cellular hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Impact of mechanical unloading on microvasculature and associated central remodeling features of the failing human heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Hemodynamic support by left ventricular assist devices reduces cardiomyocyte DNA content in the failing human heart.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Left ventricular assist device and drug therapy for the reversal of heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Reversal of severe heart failure with a continuous-flow left ventricular assist device and pharmacological therapy: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Clinical applications of stem cells for the heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Paracrine mechanisms of stem cell reparative and regenerative actions in the heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Partial left ventriculectomy to improve left ventricular function in end-stage heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Results of partial left ventriculectomy for dilated cardiomyopathy: hemodynamic, clinical and echocardiographic observations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Coronary bypass surgery with or without surgical ventricular reconstruction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Pharmacotherapy: inhibiting LV remodeling—the need for a targeted approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Relation between myocardial function and expression of sarcoplasmic reticulum Ca(2+)-ATPase in failing and nonfailing human myocardium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

SUMO1-dependent modulation of SERCA2a in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Ca2+/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Decreased Catecholamine Sensitivity and β-Adrenergic-Receptor Density in Failing Human Hearts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Mechanism of beta-adrenergic receptor desensitization in cardiac hypertrophy is increased beta-adrenergic receptor kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Myocardial adeno-associated virus serotype 6-betaARKct gene therapy improves cardiac function and normalizes the neurohormonal axis in chronic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

S100A1 decreases calcium spark frequency and alters their spatial characteristics in permeabilized adult ventricular cardiomyocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Ca2+ -dependent interaction of S100A1 with the sarcoplasmic reticulum Ca2+ -ATPase2a and phospholamban in the human heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Titin-actin interaction in mouse myocardium: passive tension modulation and its regulation by calcium/S100A1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Ca2+ -dependent interaction of S100A1 with F1-ATPase leads to an increased ATP content in cardiomyocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

S100A1 gene therapy for heart failure: A novel strategy on the verge of clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Cardiac adenoviral S100A1 gene delivery rescues failing myocardium

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

De novo cardiomyocytes from within the activated adult heart after injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

CaMKII in myocardial hypertrophy and heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Death, Cardiac Dysfunction, and Arrhythmias Are Increased by Calmodulin Kinase II in Calcineurin Cardiomyopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

PKC isozymes in chronic cardiac disease: possible therapeutic targets?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

PKC-alpha regulates cardiac contractility and propensity toward heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Protein kinase Cα as a heart failure therapeutic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

G alpha(q)-mediated activation of GRK2 by mechanical stretch in cardiac myocytes: the role of protein kinase C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Protein Kinase Cα Negatively Regulates Systolic and Diastolic Function in Pathological Hypertrophy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Protein kinase C{alpha}, but not PKC{beta} or PKC{gamma}, regulates contractility and heart failure susceptibility: implications for ruboxistaurin as a novel therapeutic approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Inhibition of protein kinase C reduces left ventricular fibrosis and dysfunction following myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Reversibility of adverse, calcineurin-dependent cardiac remodeling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

TRP-ing up heart and vessels: canonical transient receptor potential channels and cardiovascular disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Effects of selective matrix metalloproteinase inhibitor (PG-116800) to prevent ventricular remodeling after myocardial infarction: results of the PREMIER (Prevention of Myocardial Infarction Early Remodeling) trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Effects of amlodipine on exercise tolerance, quality of life, and left ventricular function in patients with heart failure from left ventricular systolic dysfunction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Rosuvastatin in older patients with systolic heart failure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCARDIO.2011.172

Structure and mechanism of the G protein-coupled receptor kinases.

31 March 2020

1 reference

12 December 2020

Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice

1 reference

12 December 2020

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

1 reference

12 December 2020

Polyploidization of heart muscle nuclei as a prerequisite for heart growth and numerical hyperplasia in heart hypertrophy

1 reference

12 December 2020

10.1038/NRCARDIO.2011.172

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1015994269

0 references

1 reference